CERE Insider Trading Activity and SEC Form 4 Filings
CERE insider trading summary
No open-market insider purchases or sales of Cerevel Therapeutics Holdings, Inc. (CERE) have been reported on SEC Form 4 in the past 12 months.
Latest CERE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 1, 2024 | N Anthony Coles | Insider | Sell | $1.0M (25,000 @ $41.18) |
| Jun 3, 2024 | N Anthony Coles | Insider | Sell | $2.0M (50,000 @ $40.61) |
| May 10, 2024 | N Anthony Coles | Insider | Sell | $2.1M (50,000 @ $42.10) |
| Apr 1, 2024 | N Anthony Coles | Insider | Sell | $2.1M (50,000 @ $42.33) |
| Mar 4, 2024 | N Anthony Coles | Insider | Sell | $2.1M (50,000 @ $41.01) |
| Feb 29, 2024 | N Anthony Coles | Insider | Sell | $2.1M (50,000 @ $41.16) |
| Feb 7, 2024 | N Anthony Coles | Insider | Sell | $104K (2,506 @ $41.54) |
| Feb 7, 2024 | John Renger | Chief Scientific Officer | Sell | $90K (2,161 @ $41.54) |
| Jan 2, 2024 | N Anthony Coles | Insider | Sell | $2.1M (50,000 @ $42.24) |
| Dec 26, 2023 | Ramiro Sanchez | Chief Medical Officer | Sell | $425K (10,000 @ $42.47) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.